作为高度选择性和口服可用的EGFRL858R/T790M/C797S 抑制剂的直接Ser797交互的Pteridine-7(8H-one衍生物
Wenzhe Jiang1, Yupei He1, Yongxiang Wang1
1School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Journal of medicinal chemistry
|August 28, 2025
概括
一种名为M49的新药有效向导致非小细胞肺癌 (NSCLC) 对奥西默蒂尼布耐药性的EGFR突变. 这种强大的抑制剂有望克服耐药性并改善患者的治疗结果.
科学领域:
- 医学化学
- 癌症学
- 药理学
背景情况:
- 在非小细胞肺癌 (NSCLC) 中获得的对 Osimertinib 的耐药性通常是由 EGFR C797S 突变驱动的.
- 需要新的小分子抑制剂来克服这种Osimertinib耐药性.
研究的目的:
- 开发针对EGFR突变,特别是EGFR L858R/T790M/C797S (EGFR LR/TM/CS) 的新型瑞丁-7(8H) 一衍生物抑制剂.
- 确定与突变的Ser797残留物和周围的疏水口袋相互作用的抑制剂.
主要方法:
- 素-7(8H) 一衍生物的设计和合成.
- 在体外酶测试以确定抑制活性 (IC50) 和激酶选择性.
- 在体内进行的药理动力学研究.
- 在 BaF3-EGFR LR/TM/CS 异种移植模型中对抗瘤疗效的评估.
主要成果:
- 化合物M49表现出强烈的EGFRLR/ TM/ CS抑制,其IC50为18. 94nM,具有很高的激酶选择性 (S35=0. 005).
- 口服M49显示出良好的药物动力学特性,其中Cmax为230. 07ng/ ml,口服生物利用率为12. 14%.
- 在BaF3-EGFR LR/ TM/ CS异种移植模型中,M49的抗瘤疗效优于Brigatinib,瘤生长抑制 (TGI) 为73. 53%,而Brigatinib为56. 05%.
结论:
- 为发现EGFRLR/TM/CS抑制剂制定了一种新的策略.
- 由于其强烈的体外和体内活性和选择性,以素-7 (素-8H) 一为基础的化合物M49是克服NSCLC对奥西默蒂尼布耐药性的有希望的候选物.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
8.8K
相关概念视频
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
